The company announced grant of 1 product patent from Canada corresponding to the new chemical entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases.
Shares of Suven Life Sciences advanced 3 percent intraday Tuesday as company secured a product patent in Canada.
The company announced grant of 1 product patent from Canada corresponding to the new chemical entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases.
This Patent is valid through 2033.
The granted claims of the patents include the class of selective 5-HT4 compound and is being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.
Venkat Jasti, CEO of Suven said, “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
At 11:03 hrs Suven Life Sciences was quoting at Rs 172.30, down Rs 0.35, or 0.20 percent on the BSE.
Posted by Rakesh Patil